Treatment of aortic disease in patients with Marfan syndrome.
Milewicz
Dianna M
DM
Department of Internal Medicine, University of Texas Medical School at Houston, 6431 Fannin, MSB 4.202, Houston, TX 77030, USA. Dianna.M.Milewicz@uth.tmc.edu
Dietz
Harry C
HC
Miller
D Craig
DC
D000293:Adolescent; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000784:Aortic Dissection / Q000453:epidemiology / Q000209:etiology / Q000601:surgery; D001014:Aortic Aneurysm / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology / Q000601:surgery*; D001019:Aortic Rupture / Q000209:etiology / Q000517:prevention & control; D001021:Aortic Valve / Q000601:surgery; D001022:Aortic Valve Insufficiency / Q000209:etiology; D019090:Case Management; D002648:Child; D005260:Female; D000071837:Fibrillins; D006801:Humans; D008297:Male; D008382:Marfan Syndrome / Q000150:complications* / Q000175:diagnosis / Q000235:genetics; D008840:Microfilament Proteins / Q000172:deficiency / Q000235:genetics; D008875:Middle Aged; D008945:Mitral Valve Prolapse / Q000209:etiology / Q000601:surgery; D009154:Mutation; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular; D012850:Sinus of Valsalva / Q000473:pathology; D015996:Survival Rate
D000319:Adrenergic beta-Antagonists; D000071837:Fibrillins; D008840:Microfilament Proteins